Novartis Presentations at the 2021 ASCO Annual Meeting
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Long-term (LT) disease control in patients (pts) with hormone receptor–positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL)